Scientists Crack How Cells Detect Damaged Mitochondria Before Parkinson's Develops
A genome-wide study reveals that diverse mitochondrial stresses funnel through a single signal—loss of membrane potential—to trigger protective cell cleanup.
Summary
Researchers at NIH used a novel MFN2-Halo reporter and genome-wide CRISPRi screens to investigate how cells recognize damaged mitochondria. The PINK1-Parkin pathway, linked to recessive Parkinson's disease, normally clears damaged mitochondria via mitophagy. The study found that diverse forms of mitochondrial damage—including protein misfolding—all converge on loss of mitochondrial membrane potential (MMP) to stall PINK1 import. This stalling occurs specifically during PINK1's transfer from the outer membrane translocase TOM to the inner membrane translocase TIM23. Without MMP or TIM23, PINK1 accumulates on the mitochondrial surface, activates Parkin, and triggers mitophagy. Cellular energy status outside mitochondria further modulates the pathway by controlling new PINK1 synthesis.
Detailed Summary
Mitochondria are the primary energy factories of cells, but they accumulate damage over time—particularly in long-lived neurons. The PINK1-Parkin pathway, encoded by two recessive Parkinson's disease genes, detects and eliminates these damaged mitochondria through selective autophagy (mitophagy). Despite decades of research, a central question remained unresolved: do the many different types of mitochondrial damage trigger this pathway through one common mechanism, or through multiple independent signals?
To address this, the NIH-based research team engineered a sensitive, quantitative single-cell reporter by endogenously tagging MFN2—one of Parkin's preferred protein substrates—with HaloTag. This MFN2-Halo reporter enabled flow cytometry-based readout of Parkin activation across entire cell populations. Using this tool, the team performed six genome-wide FACS-based CRISPRi screens in three cell lines (including cells expressing endogenous Parkin for the first time), with and without OXPHOS inhibitor treatment. The screens identified both activators and facilitators of the PINK1-Parkin pathway at unprecedented resolution.
The key finding was that diverse mitochondrial insults—pharmacological OXPHOS inhibition, protein misfolding (e.g., via LONP1 loss), and other stresses—all converge on a single trigger: loss of mitochondrial membrane potential (MMP). Critically, protein misfolding was previously hypothesized to activate PINK1 by disrupting the ATP-dependent PAM (presequence translocase-associated import motor) complex rather than the MMP. However, single-cell and single-organelle measurements in this study showed that matrix protein misfolding activates PINK1-Parkin only in mitochondria that have also lost MMP, refuting the PAM-centric model. Endogenous PINK1 import was found to rely primarily on MMP, with PAM playing only a supporting role.
Mechanistically, the team demonstrated that loss of MMP stalls PINK1 specifically during its transfer from the TOM (outer membrane translocase) complex to the TIM23 (inner membrane translocase) complex. Ablation of TIM23 was sufficient to arrest PINK1 within TOM and activate Parkin—even in mitochondria with preserved MMP—placing TIM23 at the gatekeeping step. The TOM complex, including the poorly characterized subunit TOMM5, was required to retain stalled PINK1 on the mitochondrial surface for Parkin activation. Additionally, cellular energy status (cytosolic ATP/ADP ratio) modulated the pathway by regulating the rate of new PINK1 protein synthesis, adding an extra layer of metabolic sensitivity.
These findings establish a unified model: nearly all physiological forms of mitochondrial damage activate PINK1-Parkin mitophagy by disrupting MMP, which stalls PINK1 import at the TOM-to-TIM23 handoff step. This convergent mechanism has important implications for Parkinson's disease biology and for developing therapies that tune mitophagy pharmacologically.
Key Findings
- Diverse mitochondrial stresses, including protein misfolding, all activate PINK1-Parkin by disrupting mitochondrial membrane potential (MMP).
- MMP—not the PAM motor complex—is the primary driving force for endogenous PINK1 import through TIM23.
- Loss of TIM23 alone is sufficient to trap PINK1 in the TOM complex and activate Parkin, even with intact MMP.
- TOM subunit TOMM5 is required to retain stalled PINK1 on the mitochondrial surface for pathway activation.
- Cytosolic energy status modulates PINK1-Parkin signaling by controlling the rate of new PINK1 protein synthesis.
Methodology
Six genome-wide FACS-based CRISPRi screens were performed across three human cell lines (HeLa with overexpressed Parkin, HeLa without Parkin, HEK293 with endogenous Parkin) using a novel endogenous MFN2-HaloTag reporter to quantify PINK1-Parkin activation at the single-cell level. Screens were run with and without OXPHOS inhibitor treatment, and mechanistic follow-up used immunoblotting, confocal microscopy, co-immunoprecipitation, and single-mitochondrion imaging.
Study Limitations
Most experiments were performed in HeLa and HEK293 cell lines, which may not fully recapitulate neuronal biology relevant to Parkinson's disease. The study focused on exogenous or acute mitochondrial damage models; whether chronic, low-grade mitochondrial damage in aging neurons uniformly triggers MMP loss requires further investigation. The role of TOMM5 and other TOM subunits in physiological PINK1 retention warrants independent structural validation.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: